Tag Archives: Eisai Ltd

Dementia Consortium (Alzheimer’s Research UK)

Summary The Dementia Consortium has been established to fund academic dementia research experts from the UK and overseas in their efforts to develop early research findings concerning Alzheimer’s Disease, and other forms of dementia, into validated drug targets. “The Dementia … Continue reading

Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pharmacological Treatments for Alzheimer’s Disease in Primary Care / Management of Cognitive Symptoms (DTB / Nursing Times)

Summary A Drug and Therapeutics Bulletin (DTB) article reviews the evidence concerning drugs prescribed for cognitive symptoms in Alzheimer’s Disease and discusses some issues in their prescription. Donepezil, galantamine and rivastigmine are licensed for mild to moderate Alzheimer’s Disease in … Continue reading

Posted in Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Management of Condition, Models of Dementia Care, NICE Guidelines, Pharmacological Treatments, Practical Advice, Quick Insights, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (Health Technology Assessment)

[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 11, June 2012]. Summary The purpose of this Health Technology Assessment was to review and update guidance to the NHS in England and Wales … Continue reading

Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Researchers (mostly), Management of Condition, National, NHS, NIHR, Pharmacological Treatments, Proposed for Next Newsletter, Systematic Reviews, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment